2019-2020 ACI SERIES
From September 2019 through April 2020, the upcoming ACI series includes programs in the following cities*:

- Charlotte, N.C. - Jan. 23, 2020
- Charleston, S.C. - Feb. 1, 2020
- Tuscon, Ariz. - March 14, 2020
- Tampa, Fla. - March 21, 2020
- Seattle - March 28, 2020
- Toronto - April 9, 2020
- Washington, D.C.

*Please visit sitcancer.org/aci for more information.

ACI PROGRAM TAKEAWAYS
ACIs are presented by local authorities in tumor immunology and cancer immunotherapy and cover the following topics:

- Treating patients with FDA-approved immunotherapies
- Interpreting new clinical data supporting the use of checkpoint inhibitors, CAR T therapies, cytokines, oncolytic viruses and vaccines
- Identifying and managing irAEs
- Employing strategies to overcome operational and reimbursement barriers to incorporating immunotherapy into your practice
- Applying foundational knowledge for clinical implementation of SITC’s Cancer Immunotherapy Guidelines
- Anticipating forthcoming immunotherapy trends/treatments/trials and how they impact your patients and practices
- Recognizing common and uncommon toxicities in immunotherapy patients and provide solutions/adjustments in treatment to address them

The 2019–2020 ACI series is jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer in collaboration with the American Academy of Emergency Medicine, the Association of Community Cancer Centers and the Hematology/Oncology Pharmacy Association.

For full accreditation information and to register for these events, please visit: sitcancer.org/aci
The 2019–2020 ACI series is jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer in collaboration with the American Academy of Emergency Medicine, the Association of Community Cancer Centers and the Hematology/Oncology Pharmacy Association.

WHY ATTEND?
- Earn CME, CPE and CNE credits and MOC points
- Attend for FREE if you are a healthcare professional, student, patient or patient advocate
- Hear from and network with local experts in tumor immunology and cancer immunotherapy

ACCREDITATION INFORMATION

AMA Credit Designation
This activity has been approved for AMA PRA Category 1 Credit(s)™.

Pharmacist Credit Designation
This activity is eligible for ACPE credit, see final CPE activity announcement for specific details.

Nursing Credit Designation
This activity is eligible for ANCC contact hours, see final CNE activity announcement for specific details.

Thank you to our dedicated organizers who make our ACI live programs so engaging and impactful:

CHARLOTTE, N.C. - JAN. 23, 2020
Asim Amin, MD, PhD – Levine Cancer Institute
Nilanjan Ghosh, MD, PhD – Levine Cancer Institute
Marina Kanos, MSN, FNP-C – Levine Cancer Institute

CHARLESTON, S.C. - FEB. 1, 2020
David M. Neskey, MD – MUSC Hollings Cancer Center
Chrystal M. Paulos, PhD – MUSC Hollings Cancer Center
Jessica Thaxton, PhD, MSCR – Medical University of South Carolina

TUCSON, ARIZ. - MARCH 14, 2020
Emmanuel Katsanis, MD – University of Arizona
Ali McBride, PharmD, MS, BCPS, BCOP, FAzPA – University of Arizona Cancer Center
Rachna Shroff, MD, MS – University of Arizona Cancer Center

TAMPA, FLA. - MARCH 21, 2020
Marco L. Davila, MD – Moffitt Cancer Center
Jose Lutzky, MD, FACP – University of Miami Sylvester Cancer Center
Christina Bachmeier, PharmD, BCOP – Moffitt Cancer Center

SEATTLE - MARCH 28, 2020
Shailender Bhattia, MD – University of Washington
Petros Grivas, MD, PhD – University of Washington

TORONTO - APRIL 9, 2020
Pamela S. Ohashi, PhD – Princess Margaret Cancer Centre, University Health Network

The 2019–2020 ACI series is jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer in collaboration with the American Academy of Emergency Medicine, the Association of Community Cancer Centers and the Hematology/Oncology Pharmacy Association.

For full accreditation information and to register for these events, please visit sitcancer.org/aci